PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as

S	many	sheets	as	necessary'

COMPLET	TE IF KNOWN
Application Number	10/649,852
Confirmation Number	7224
Filing Date	08/27/2003
First Named Inventor	Robert Joseph Isfort
Group Art Unit	1647
Examiner Name	Shulamith H. Shafer
Attorney Docket Number	8448R

SHEET l of 2

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ¹ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.'	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T*
945	1	WO 97/00063 A2	01/03/1997	Vale, et al.		
OF	2	EP 0 860 501 A2	08/26/1998	Lovenberg, et al.		
D	3	WO 96/37223 A1	11/28/1996	Grabstein, et al.		
				D. W. CONSTRUCTOR		
EXAMINEROUNUL H (Value DATE CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/5/2004)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO COMPLETE IF KNOWN Application Number 10/649,852 INFORMATION DISCLOSURE Confirmation Number 7224 08/27/2003 Filing Date STATEMENT BY APPLICANT (use as many sheets as necessary) First Named Inventor Robert Joseph Isfort Group Art Unit 1647 **Examiner Name** Shulamith H. Shafer SHEET 2 of 2 Attorney Docket Number 8448R

NON PATENT LITERATURE DOCUMENTS

EXAMINE R INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T³			
an	.4	H.A. THOMAS, ET AL., "CRF and Related Peptides as Anti-Inflammatory Agonists", Annals New York Academy of Sciences, 1993, Vol. 697, pp. 219-228.				
(p)	5	.R. MCCARTHY, ET AL., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents", Annual Reports in Medicinal Chemistry, 1999, Vol. 34, Academic Press, pp.11-20,				
-						
EXAMINE	R (Warnth & Charles DATE CONSIDERED				

EXAMINER: Initial I reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/4/2004)